Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasm, Residual × talquetamab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 26 Recurrence 3 Hematologic Neoplasms 2 Waldenstrom Macroglobulinemia 1 Neoplasm, Residual 1 Cytokine Release Syndrome 1

Interventions

Cyclophosphamide 20 blinatumomab 16 fludarabine 13 Cytarabine 13 Azacitidine 11 venetoclax 9 fludarabine phosphate 9 Rituximab 7 Dexamethasone 7 Methotrexate 6 Lenalidomide 6 Daunorubicin 6 daratumumab 4 Whole-Body Irradiation 4 Vincristine 4 Mercaptopurine 4 Melphalan 4 Idarubicin 4 Etoposide 4 obinutuzumab 3 Imatinib Mesylate 3 Granulocyte Colony-Stimulating Factor 3 Cladribine 3 Busulfan 3 Asparaginase 3 tisagenlecleucel 2 thymoglobulin 2 pembrolizumab 2 palbociclib 2 nilotinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06993675 2025-08-29

ROTATE

Yale University

Phase 2 Recruiting

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡